A slow-but-steady decline in fortune continues at Trimeris, once one of the Triangle's most-promising biotechnology companies.
Late Wednesday, the Durham-based company reported that second-quarter sales of its HIV/AIDS drug Fuzeon were $29.1 million, down 24 percent from the same quarter last year. Sales in the U.S. and Canada were off 39 percent.
Trimeris has slashed its operations and workforce in recent years as demand weakened for Fuzeon. The drug, sold with partner Roche, is one of the few remaining assets at Trimeris.
The company's stock closed Wednesday at $2.01, down 1 cent.